FOXM1 and neoplasm: We validated FOXM1 for the first time as a critical therapeutic target in TNBC using genetic siRNA technology, resulting in significant inhibition of TNBC tumor xenografts in mice [62], suggesting that that FOXM1 represents an Achilles heel for targeting TNBC.